Article - 28/10/2013 University of Hohenheim – a strong commitment to the bioeconomy The bioeconomy is not only a major social challenge. It is also a complex thematic area that covers many scientific fields. The University of Hohenheim in Stuttgart has just published a strategy paper with the bioeconomy as a core topic of its research activities. Heike Laue talked with the universitys rector Prof. Dr. Stephan Dabbert about the paper.https://www.gesundheitsindustrie-bw.de/en/article/news/university-of-hohenheim-a-strong-commitment-to-the-bioeconomy
Article - 12/08/2013 Baden-Württemberg – strategies for the future of biodiversity conservation The alarming decline in animal and plant species stands more chance to be stopped by action on local and regional levels than through global conventions. Research and action programmes by German federal and state governments can help preserve biodiversity in Baden-Württemberg.https://www.gesundheitsindustrie-bw.de/en/article/news/baden-wuerttemberg-strategies-for-the-future-of-biodiversity-conservation
Article - 11/03/2013 Trenzyme – optimal expression of recombinant proteins Trenzyme GmbH in Konstanz offers services and products in the fields of genomics and proteomics. The company specialises in contract research and custom R&D services and is also working on new and improved products and processes. The company recently developed a new method for the rapid identification of optimal expression conditions for recombinant proteins. https://www.gesundheitsindustrie-bw.de/en/article/news/trenzyme-optimal-expression-of-recombinant-proteins
Article - 18/02/2013 Biotechnology in Biberach: a success story that breaks new ground At its New Year reception Biberach University of Applied Sciences outlined the universitys success the establishment of its biotechnology programme is going smoothly and student interest remains steady. Biberach also has a successful track record of acquiring third-party funding and has established new national and international cooperations.https://www.gesundheitsindustrie-bw.de/en/article/news/biotechnology-in-biberach-a-success-story-that-breaks-new-ground
Article - 15/10/2012 gerbion®: hunting down pathogens Detecting viruses, bacteria or parasites in human, animal, food and environmental samples is routine for the staff of gerbion GmbH & Co. KG. The company has been using virological, microbiological and serological methods for many years, but is now also using cutting-edge molecular biology methods for detecting pathogens. The founders of the Kornwestheim-based diagnostics company have concentrated on own research work and the development of…https://www.gesundheitsindustrie-bw.de/en/article/news/gerbion-hunting-down-pathogens
Article - 14/10/2011 Vetter - a world market leader: “We put ourselves in our clients’ shoes" We talked with Peter Soelkner Managing Director of Vetter Pharma International GmbH. Soelkner has been with Vetter since 2008. Prior to his current position Soelkner was the head of Key Account Management at Vetter before going on to work for Sartorius Stedim Biotech USA. The sales specialist has a chemical engineering degree and an MBA from Columbia University NY.https://www.gesundheitsindustrie-bw.de/en/article/news/vetter-a-world-market-leader-we-put-ourselves-in-our-clients-shoes
Article - 14/01/2009 Strict requirements for the market approval of tissue engineering products New regulations for the marketing approval of advanced therapy medicinal products have applied in the EU since December 2008. Prof. Sabine Kloth from TÜV SÜD Product Service GmbH is an expert in materials of animal origin and has been closely following the formulation of the ATMP Regulation. https://www.gesundheitsindustrie-bw.de/en/article/news/strict-requirements-for-the-market-approval-of-tissue-engineering-products
Article - 20/06/2008 Zeiss expects successful end to first six months of 2007/2008 The optics and electronics specialist Carl Zeiss AG Oberkochen is optimistic about the first six months of 20072008 30th September despite decreasing investment activity in the semiconductor industry. For the second six months the company expects a slight slowdown in the revenues the company generates in this business group. In the first half of the fiscal year the Semiconductor Technology Group recorded further strong growth up 16 and generated…https://www.gesundheitsindustrie-bw.de/en/article/news/zeiss-expects-successful-end-to-first-six-months-of-2007-2008
Article - 26/05/2015 Novel effect of B-Raf inhibitors against bowel cancer discovered Colorectal carcinoma is the most frequent type of bowel cancer and the second most common tumour disease in men and women in Germany. A particularly aggressive form occurs when a mutation is present in the proto-oncogene BRAF. As part of the Collaborative Research Centre 850 at the Institute of Molecular Medicine and Cell Research at the University of Freiburg, Dr. Ricarda Herr and Dr. Tilman Brummer are trying to find out how a mutated BRAF gene…https://www.gesundheitsindustrie-bw.de/en/article/news/novel-effect-of-b-raf-inhibitors-against-bowel-cancer-discovered
Article - 26/05/2015 Does too much beef and cow’s milk cause cancer? The large number of breast and colon cancer cases might be due to viruses that are taken up with beef and dairy products. This is the provocative thesis of Nobel Laureate Harald zur Hausen who previously linked HPV with cervical cancer. In addition to epidemiological evidence, zur Hausen and his team have also provided experimental evidence to substantiate his thesis.https://www.gesundheitsindustrie-bw.de/en/article/news/does-too-much-beef-and-cows-milk-cause-cancer
Article - 22/06/2015 Through the nose directly into the brain: Biberach researchers are working on a novel way to apply pharmaceuticals The blood-brain barrier prevents most drugs, and large biologics in particular, from entering the brain. This physiological barrier impairs the study of central nervous system (CNS) diseases such as Alzheimer’s, Parkinson’s and multiple sclerosis as well as the development of drugs. However, there is a hidden side entrance to the brain, which means that there is a way to circumvent this barrier.https://www.gesundheitsindustrie-bw.de/en/article/news/through-the-nose-directly-into-the-brain-biberach-researchers-are-working-on-a-novel-way-to-apply-pharmaceuticals
Article - 22/06/2015 Attentive observer of metabolic processes Physicist Dr. Jan-Bernd Hövener makes magnetic resonance imaging devices smaller and their magnetic fields weaker in the hope that precisely these properties will help him detect abnormal metabolic processes and tumours. On 9th June 2015, the International Organisation for Medical Physics (IOMP) awarded Hövener the Young Scientist Award in Medical Physics, the organisation’s most important prize for up-and-coming scientists. https://www.gesundheitsindustrie-bw.de/en/article/news/attentive-observer-of-metabolic-processes
Epigenetics - 10/08/2015 Reading domains detect and identify histone modifications Prof. Dr. Albert Jeltsch from the Institute of Biochemistry at the University of Stuttgart and his team of researchers have now presented an alternative method to detect and identify changes in the post-translational modifications of histones. They envisage that their new method, which uses parts of natural proteins, so-called reading domains, will make such tests cheaper and simpler, and experimental data more reliable. https://www.gesundheitsindustrie-bw.de/en/article/news/reading-domains-detect-and-identify-histone-modifications
Article - 24/08/2015 Autranomics – high-throughput cell production Manual work is out – the rapid production of cells that carry foreign genetic material for use in research and industry can only be achieved with a high degree of automation. A fully automated process is needed to cultivate, analyse and select the cells. One such automated system has been developed by the Fraunhofer Society and the Max Planck Society in a collaborative project called Autranomics.https://www.gesundheitsindustrie-bw.de/en/article/news/autranomics-high-throughput-cell-production
Article - 21/09/2015 Hans-Peter Deigner: "Optimisation of lateral flow assays using nanoparticles." Nanoparticles are already used in many materials and areas, ranging from textiles to scientific and medical research. The global scientific community is keenly interested in nanoparticle research and Prof. Dr. Hans-Peter Deigner, professor in the Faculty of Medical and Life Sciences at Furtwangen University of Applied Sciences (HFU) is no exception. Deigner works on optimising nanoparticles for application in lateral flow assays. As well as…https://www.gesundheitsindustrie-bw.de/en/article/news/hans-peter-deigner-optimisation-of-lateral-flow-assays-using-nanoparticles
Article - 05/10/2015 Nanoparticles make eye drops more effective Drops are a common way of applying drugs for treating a wide of range of eye diseases. Most of us have used eye drops at least once in our lives, but we are not usually aware that even if the drops are applied correctly, only one percent of the drug reaches the eye. The rest is flushed out by eyelid movement or with tear fluid. So very high drug concentrations are needed, and the downside of this is that it can cause substantial adverse effects.…https://www.gesundheitsindustrie-bw.de/en/article/news/nanoparticles-make-eye-drops-more-effective
Article - 23/11/2015 Double-secured immune protection against plant attackers Plants have sophisticated defence mechanisms to help them fight off all kinds of pathogens. A group of researchers led by Dr. Gabriel Schaaf at the University of Tübingen’s ZMBP has now discovered that plants’ immune response is more similar to the innate immune system of humans and animals than previously thought. https://www.gesundheitsindustrie-bw.de/en/article/news/double-secured-immune-protection-against-plant-attackers
Article - 16/12/2015 Small and handy – tiny LED lights can improve eye surgeons’ work A new lighting system for vitreoretinal surgery that uses small white light-emitting diode (LED) technology, promises to be safer for patients and more practical for surgeons. It will probably be three years before the idea is launched as a medical product. Prototypes need to be optimised, approved and then tested for safety and functionality at the University Eye Hospital in Frankfurt. https://www.gesundheitsindustrie-bw.de/en/article/news/small-and-handy-tiny-led-lights-can-improve-eye-surgeons-work
Article - 14/12/2015 Cathepsin L: overcoming stress in tumours Cathepsins are proteases, i.e. enzymes that break down proteins into smaller fragments. They are also involved in the formation of new blood vessels and wound healing. Another thing that cathepsins do is help tumours spread and form metastases in the body. Prof. Dr. Thomas Reinheckel and his team from the Institute of Molecular Medicine and Cell Research at the University of Freiburg are studying how this happens. Insights into the role of…https://www.gesundheitsindustrie-bw.de/en/article/news/cathepsin-l-den-stress-im-tumor-ueberwinden
Article - 07/01/2016 New protein helps B cells generate an effective immune response The human immune system plays a key role for human health. Dr. Gina Fiala, a scientist in Prof. Dr. Wolfgang Schamel’s team in the Department of Immunology at Freiburg University, has discovered Kidins220/ARMS in B cells. Kidins220/ARMS is part of the adaptive immune system where it plays a key role in the maturation of B cells.https://www.gesundheitsindustrie-bw.de/en/article/news/kidins220-hilft-b-zellen-bei-der-immunabwehr
Article - 28/01/2016 Crowdsourcing initiative to tackle Alzheimer’s The BioMed X Innovation Center and the biopharmaceutical company AbbVie Deutschland GmbH & Co. KG have used crowdsourcing to set up a team of scientists from renowned international institutions to investigate new options for treating Alzheimer’s disease. The team are looking for targets in the metabolism of tau proteins and its pathological modifications that can be used to develop drugs to treat Alzheimer’s disease.https://www.gesundheitsindustrie-bw.de/en/article/news/crowdsourcing-initiative-to-tackle-alzheimers
Article - 22/02/2016 Generating malaria parasite gene deletion mutants The fight against malaria is one of the targets of goal 3 of the Sustainable Development Goals (SDGs) (ensuring healthy lives and promote well-being for all at all ages). The research carried out by Prof. Dr. Frischknecht and Mirko Singer from the Centre for Infectious Diseases at Heidelberg University Hospital is one of several steps towards eradicating malaria. https://www.gesundheitsindustrie-bw.de/en/article/news/generating-malaria-parasite-gene-deletion-mutants
Article - 11/04/2016 Glycovirology: carbohydrate molecules against infections Many viruses enter cells by way of carbohydrate molecules known as glycans to which they bind during the initial steps of infection. However, it is still largely unknown how glycan-mediated infection proceeds. This is about to change with a working group that has been set up by the DFG at the University of Tübingen and five other universities. The group will focus on glycovirology, a new scientific area that aims to understand the…https://www.gesundheitsindustrie-bw.de/en/article/news/glycovirology-carbohydrate-molecules-against-infections
Article - 12/05/2016 Novel method for predicting the spatial structure of biomolecules Biomolecules can only fulfil their functions in the cell when they fold into a characteristic native three-dimensional structure. Knowing this structure is not only of paramount importance for basic research, but also for medicine and pharmacology. Scientists from the Karlsruhe Institute of Technology (KIT) have therefore developed a simple method to predict the three-dimensional structure of biomolecules from the analysis of readily available…https://www.gesundheitsindustrie-bw.de/en/article/news/novel-method-for-predicting-the-spatial-structure-of-biomolecules
Article - 30/05/2016 The unknown dark spot of the microcosm The world of microorganisms is still largely unknown. Researchers such as Kai Sohn from the Fraunhofer IGB in Stuttgart are working on decoding, analysing and gradually gaining a better understanding of the microbial genome. In their search for new enzymes and other biomolecules, both biotechnologists and pharmacologists are interested in micoorganisms, and physicians are hoping that detailed insights into the microbial genome will lead to the…https://www.gesundheitsindustrie-bw.de/en/article/news/the-unknown-dark-spot-of-the-microcosm